“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To directly address the issue of metabolic heterogeneity in can...
Uložené v:
| Vydané v: | Frontiers in oncology Ročník 8; s. 677 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Switzerland
Frontiers Media S.A
05.02.2019
|
| Predmet: | |
| ISSN: | 2234-943X, 2234-943X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To directly address the issue of metabolic heterogeneity in cancer, we purified a new distinct sub-population of CSCs, based solely on their energetic profile. We propose the term "energetic" cancer stem cells (e-CSCs), to better describe this novel cellular phenotype. In a single step, we first isolated an auto-fluorescent cell sub-population, based on their high flavin-content, using flow-cytometry. Then, these cells were further subjected to a detailed phenotypic characterization. More specifically, e-CSCs were more glycolytic, with higher mitochondrial mass and showed significantly elevated oxidative metabolism. e-CSCs also demonstrated an increased capacity to undergo cell cycle progression, as well as enhanced anchorage-independent growth and ALDH-positivity. Most importantly, these e-CSCs could be effectively targeted by treatments with either (i) OXPHOS inhibitors (DPI) or (ii) a CDK4/6 inhibitor (Ribociclib). Finally, we were able to distinguish two distinct phenotypic sub-types of e-CSCs, depending on whether they were grown as 2D-monolayers or as 3D-spheroids. Remarkably, under 3D anchorage-independent growth conditions, e-CSCs were strictly dependent on oxidative mitochondrial metabolism. Unbiased proteomics analysis demonstrated the up-regulation of gene products specifically related to the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Therefore, mitochondrial inhibitors should be further developed as promising anti-cancer agents, to directly target and eliminate the "fittest" e-CSCs. Our results have important implications for using e-CSCs, especially those derived from 3D-spheroids, (i) in tumor tissue bio-banking and (ii) as a new cellular platform for drug development. |
|---|---|
| AbstractList | Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To directly address the issue of metabolic heterogeneity in cancer, we purified a new distinct sub-population of CSCs, based solely on their energetic profile. We propose the term "energetic" cancer stem cells (e-CSCs), to better describe this novel cellular phenotype. In a single step, we first isolated an auto-fluorescent cell sub-population, based on their high flavin-content, using flow-cytometry. Then, these cells were further subjected to a detailed phenotypic characterization. More specifically, e-CSCs were more glycolytic, with higher mitochondrial mass and showed significantly elevated oxidative metabolism. e-CSCs also demonstrated an increased capacity to undergo cell cycle progression, as well as enhanced anchorage-independent growth and ALDH-positivity. Most importantly, these e-CSCs could be effectively targeted by treatments with either (i) OXPHOS inhibitors (DPI) or (ii) a CDK4/6 inhibitor (Ribociclib). Finally, we were able to distinguish two distinct phenotypic sub-types of e-CSCs, depending on whether they were grown as 2D-monolayers or as 3D-spheroids. Remarkably, under 3D anchorage-independent growth conditions, e-CSCs were strictly dependent on oxidative mitochondrial metabolism. Unbiased proteomics analysis demonstrated the up-regulation of gene products specifically related to the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Therefore, mitochondrial inhibitors should be further developed as promising anti-cancer agents, to directly target and eliminate the "fittest" e-CSCs. Our results have important implications for using e-CSCs, especially those derived from 3D-spheroids, (i) in tumor tissue bio-banking and (ii) as a new cellular platform for drug development. Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To directly address the issue of metabolic heterogeneity in cancer, we purified a new distinct sub-population of CSCs, based solely on their energetic profile. We propose the term "energetic" cancer stem cells (e-CSCs), to better describe this novel cellular phenotype. In a single step, we first isolated an auto-fluorescent cell sub-population, based on their high flavin-content, using flow-cytometry. Then, these cells were further subjected to a detailed phenotypic characterization. More specifically, e-CSCs were more glycolytic, with higher mitochondrial mass and showed significantly elevated oxidative metabolism. e-CSCs also demonstrated an increased capacity to undergo cell cycle progression, as well as enhanced anchorage-independent growth and ALDH-positivity. Most importantly, these e-CSCs could be effectively targeted by treatments with either (i) OXPHOS inhibitors (DPI) or (ii) a CDK4/6 inhibitor (Ribociclib). Finally, we were able to distinguish two distinct phenotypic sub-types of e-CSCs, depending on whether they were grown as 2D-monolayers or as 3D-spheroids. Remarkably, under 3D anchorage-independent growth conditions, e-CSCs were strictly dependent on oxidative mitochondrial metabolism. Unbiased proteomics analysis demonstrated the up-regulation of gene products specifically related to the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Therefore, mitochondrial inhibitors should be further developed as promising anti-cancer agents, to directly target and eliminate the "fittest" e-CSCs. Our results have important implications for using e-CSCs, especially those derived from 3D-spheroids, (i) in tumor tissue bio-banking and (ii) as a new cellular platform for drug development.Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To directly address the issue of metabolic heterogeneity in cancer, we purified a new distinct sub-population of CSCs, based solely on their energetic profile. We propose the term "energetic" cancer stem cells (e-CSCs), to better describe this novel cellular phenotype. In a single step, we first isolated an auto-fluorescent cell sub-population, based on their high flavin-content, using flow-cytometry. Then, these cells were further subjected to a detailed phenotypic characterization. More specifically, e-CSCs were more glycolytic, with higher mitochondrial mass and showed significantly elevated oxidative metabolism. e-CSCs also demonstrated an increased capacity to undergo cell cycle progression, as well as enhanced anchorage-independent growth and ALDH-positivity. Most importantly, these e-CSCs could be effectively targeted by treatments with either (i) OXPHOS inhibitors (DPI) or (ii) a CDK4/6 inhibitor (Ribociclib). Finally, we were able to distinguish two distinct phenotypic sub-types of e-CSCs, depending on whether they were grown as 2D-monolayers or as 3D-spheroids. Remarkably, under 3D anchorage-independent growth conditions, e-CSCs were strictly dependent on oxidative mitochondrial metabolism. Unbiased proteomics analysis demonstrated the up-regulation of gene products specifically related to the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Therefore, mitochondrial inhibitors should be further developed as promising anti-cancer agents, to directly target and eliminate the "fittest" e-CSCs. Our results have important implications for using e-CSCs, especially those derived from 3D-spheroids, (i) in tumor tissue bio-banking and (ii) as a new cellular platform for drug development. |
| Author | Fiorillo, Marco Lisanti, Michael P. Sotgia, Federica |
| AuthorAffiliation | 1 Biomedical Research Centre (BRC), Translational Medicine, School of Environment and Life Sciences, University of Salford , Manchester , United Kingdom 2 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria , Cosenza , Italy |
| AuthorAffiliation_xml | – name: 1 Biomedical Research Centre (BRC), Translational Medicine, School of Environment and Life Sciences, University of Salford , Manchester , United Kingdom – name: 2 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria , Cosenza , Italy |
| Author_xml | – sequence: 1 givenname: Marco surname: Fiorillo fullname: Fiorillo, Marco – sequence: 2 givenname: Federica surname: Sotgia fullname: Sotgia, Federica – sequence: 3 givenname: Michael P. surname: Lisanti fullname: Lisanti, Michael P. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30805301$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1O3DAUha2KqsCUdXeVl1RqBv_FSbpAQiktSNAiQaXuLMe-mTHK2FMnA5odyz5E-3I8ST0zUEGlemPL957vSPeeXbTlgweE3lAy5rysDtrgzZgRWo4JkUXxAu0wxkVWCf5968l7G-31_TVJR-aEEv4KbXNSkpwTuoN-3t_9OvYQJzA4c3_3G9faG4j4coAZrqHrerwPWX1Z9-8-4CP8BW7xyXIOMTuHQTehcwZrb_FFTM8Woh7cDeCrxSzEtRpfTMGHISne448x1TxulvjcDcFMg7fR6Q6v7Zev0ctWdz3sPdwj9O3T8VV9kp19_XxaH51lRuTVkDFoTG45qUibtzkwEEXRSJ6LEhoJrKSCMduU2lJrS1bR1hpBaG6skNZaBnyETjdcG_S1mkc303GpgnZq_RHiROmYZtGBkoaX0hSsLUUlKLBKCKgSg1VGG5PmO0KHG9Z80czAGvBD1N0z6POKd1M1CTdK8oJIKRJg_wEQw48F9IOaud6kuWkPYdErRktJBckLklrfPvX6a_K4ytSQbxpMDH0foVXGDWkfYWXtOkWJWqVGrVKjVqlR69Qk3cE_ukf0_xR_AK8ix5c |
| CitedBy_id | crossref_primary_10_3390_ijms241411540 crossref_primary_10_1016_j_cytogfr_2019_12_002 crossref_primary_10_1016_j_yexcr_2024_114213 crossref_primary_10_1016_j_mito_2021_11_002 crossref_primary_10_1186_s12885_019_6018_1 crossref_primary_10_3390_cancers16020355 crossref_primary_10_3390_cancers12092492 crossref_primary_10_1186_s12967_023_04498_5 crossref_primary_10_3389_fonc_2021_740720 crossref_primary_10_1016_j_bbamcr_2025_119910 crossref_primary_10_1080_14789450_2019_1654862 crossref_primary_10_3389_fonc_2019_00159 crossref_primary_10_3389_fonc_2019_00753 crossref_primary_10_3389_fonc_2019_01003 crossref_primary_10_3389_pore_2023_1610996 crossref_primary_10_3390_ijms24086945 crossref_primary_10_1093_carcin_bgz126 crossref_primary_10_3390_biomedicines12071576 crossref_primary_10_1186_s12885_021_08813_5 crossref_primary_10_3390_cancers15041192 crossref_primary_10_1016_j_cytogfr_2021_02_001 crossref_primary_10_3389_fonc_2021_678343 crossref_primary_10_3390_cancers15071936 crossref_primary_10_3390_cells9020407 crossref_primary_10_1016_j_bcp_2023_115913 crossref_primary_10_3390_cells9081819 crossref_primary_10_3389_fonc_2020_01528 crossref_primary_10_3390_cells9071651 crossref_primary_10_1016_j_freeradbiomed_2021_09_024 crossref_primary_10_1016_j_chembiol_2021_11_002 crossref_primary_10_3390_cancers12092482 crossref_primary_10_1016_j_bbadis_2024_167549 crossref_primary_10_1016_j_bbadis_2023_166897 crossref_primary_10_1111_1440_1681_13528 crossref_primary_10_3390_cancers12061645 crossref_primary_10_3390_cells10030705 crossref_primary_10_3389_fcell_2022_849962 crossref_primary_10_2174_011874091X307243240513092933 crossref_primary_10_1038_s41418_021_00788_x crossref_primary_10_1016_j_semcancer_2020_05_006 crossref_primary_10_3390_molecules27051468 crossref_primary_10_1016_j_drup_2019_100643 crossref_primary_10_3389_fonc_2020_00299 crossref_primary_10_1038_s41467_023_39854_y crossref_primary_10_1038_s41586_025_09176_8 crossref_primary_10_3390_cells9061529 crossref_primary_10_1002_advs_202308632 |
| Cites_doi | 10.18632/aging.100941 10.18632/oncotarget.5401 10.1080/14737140.2018.1435275 10.18632/oncotarget.9122 10.1126/science.959840 10.1016/S0006-3495(02)75621-X 10.15430/JCP.2014.19.2.111 10.15407/ubj88.01.031 10.3892/ijo.2016.3582 10.18632/aging.101304 10.1038/srep18772 10.18632/oncotarget.4401 10.1016/j.abb.2013.02.015 10.1016/j.ctrv.2017.09.003 10.1186/bcr2583 10.1016/j.bbrc.2017.11.117 10.18632/oncotarget.19612 10.1111/j.1742-4658.2011.08202.x 10.18632/aging.100983 10.1159/000481656 10.1007/s12282-017-0827-3 10.1038/nature10762 10.1016/j.canlet.2015.10.012 10.1016/j.neo.2015.11.006 10.1182/blood-2015-12-688051 10.3892/ijo.2016.3551 10.1038/s41467-018-04470-8 10.1038/nature25167 10.1373/clinchem.2016.263582 10.2217/Bmm.10.1 10.1038/bjc.2014.201 10.18632/oncotarget.15852 10.1007/s12282-018-0848-6 10.18632/oncotarget.2789 10.1016/j.ccell.2018.03.023 10.1021/acs.jproteome.7b00761 10.1038/emm.2016.103 10.1038/nrclinonc.2016.60 10.1016/j.jprot.2018.02.015 10.1038/nature12624 10.18632/aging.101351 10.1042/Bcj20170164 10.1016/j.critrevonc.2013.09.001 10.1080/17512433.2017.1376653 10.1186/s12943-017-0600-4 10.1007/s10911-012-9255-3 10.1080/15384101.2018.1515551 10.1038/nmeth.3112 10.1007/978-1-4939-2257-4_23 10.18632/oncotarget.17688 10.18632/aging.100808 10.1186/s13058-016-0712-6 10.1038/nature09781 10.1073/pnas.1602379113 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Fiorillo, Sotgia and Lisanti. 2019 Fiorillo, Sotgia and Lisanti |
| Copyright_xml | – notice: Copyright © 2019 Fiorillo, Sotgia and Lisanti. 2019 Fiorillo, Sotgia and Lisanti |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fonc.2018.00677 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2234-943X |
| ExternalDocumentID | oai_doaj_org_article_6c386c72f84941e2944e9d2e29cacc22 PMC6370664 30805301 10_3389_fonc_2018_00677 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM ACXDI IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c459t-2ebc5d3090f5f5e2e477b63548eb6e281422db8ad1dd8291fdc4015cd46ddd2e3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 54 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000457672100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2234-943X |
| IngestDate | Fri Oct 03 12:45:52 EDT 2025 Thu Aug 21 18:24:27 EDT 2025 Thu Sep 04 20:24:17 EDT 2025 Thu Apr 03 07:07:40 EDT 2025 Sat Nov 29 01:49:02 EST 2025 Tue Nov 18 22:26:20 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Ribociclib mitochondrial OXPHOS cancer stem-like cells (CSCs) metabolism Diphenyleneiodonium (DPI) glycolysis |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c459t-2ebc5d3090f5f5e2e477b63548eb6e281422db8ad1dd8291fdc4015cd46ddd2e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Francesco De Francesco, Azienda Ospedaliero Universitaria Ospedali Riuniti, Italy; Cesar Cardenas, Universidad Mayor, Chile Edited by: Massimo Bonora, Albert Einstein College of Medicine, United States This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology |
| OpenAccessLink | https://doaj.org/article/6c386c72f84941e2944e9d2e29cacc22 |
| PMID | 30805301 |
| PQID | 2186140570 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6c386c72f84941e2944e9d2e29cacc22 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6370664 proquest_miscellaneous_2186140570 pubmed_primary_30805301 crossref_citationtrail_10_3389_fonc_2018_00677 crossref_primary_10_3389_fonc_2018_00677 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-02-05 |
| PublicationDateYYYYMMDD | 2019-02-05 |
| PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-05 day: 05 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in oncology |
| PublicationTitleAlternate | Front Oncol |
| PublicationYear | 2019 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Ozsvari (B4) 2016; 8 Peiris-Pages (B1) 2016; 18 Miranda-Lorenzo (B14) 2014; 11 Lamb (B5) 2014; 5 Lienhart (B8) 2013; 535 Lim (B49) 2016; 49 Meacham (B53) 2013; 501 De Luca (B26) 2015; 6 Yang (B37) 2018; 17 de Groot (B35) 2017; 60 Wu (B45) 2016; 49 Wang (B42) 2017; 8 Visvader (B54) 2011; 469 Burris (B32) 2018; 18 Martinez-Outschoorn (B3) 2017; 14 Fiorillo (B22) 2017; 8 Shah (B29) 2018; 32 Iwata (B33) 2018; 25 Sotgia (B6) 2018; 17 de Francesco (B2) 2018; 475 Echavarria (B34) 2017; 12 Alix-Panabieres (B43) 2017; 63 Ramos-Esquivel (B31) 2018; 25 Greaves (B52) 2012; 481 Yan (B44); 110 Macheroux (B9) 2011; 278 Zhou (B47) 2013; 88 Ozsvari (B28) 2017; 9 Huang (B11); 82 Kang (B41) 2016; 48 Smith (B25) 2018; 177 Shah (B15) 2015; 17 Milanovic (B39) 2018; 553 Sotgia (B27) 2017; 8 Farnie (B7) 2015; 6 Zangardi (B36) 2017; 10 Karimi-Busheri (B38) 2010; 12 No (B46) 2014; 19 Prasetyanti (B55) 2017; 16 Bartolome (B13) 2015; 1264 Nowell (B51) 1976; 194 Danylovych (B12) 2016; 88 Morata-Tarifa (B17) 2016; 6 Klein (B30) 2018; 34 Fiorillo (B21) 2016; 7 Li (B48) 2018; 495 Shaw (B18) 2012; 17 Fiorillo (B20) 2016; 8 Ozsvari (B23) 2017; 9 Peiris-Pages (B24) 2015; 7 You (B16) 2018; 9 Johnson (B19) 2016; 128 Heikal (B10) 2010; 4 Patel (B40) 2016; 113 de Aberasturi (B50) 2016; 370 |
| References_xml | – volume: 8 start-page: 567 year: 2016 ident: B4 article-title: Repurposing of FDA-approved drugs against cancer - focus on metastasis publication-title: Aging doi: 10.18632/aging.100941 – volume: 6 start-page: 30472 year: 2015 ident: B7 article-title: High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant publication-title: Oncotarget doi: 10.18632/oncotarget.5401 – volume: 18 start-page: 201 year: 2018 ident: B32 article-title: Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer publication-title: Expert Rev Anticancer Ther. doi: 10.1080/14737140.2018.1435275 – volume: 7 start-page: 34084 year: 2016 ident: B21 article-title: Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells publication-title: Oncotarget doi: 10.18632/oncotarget.9122 – volume: 194 start-page: 23 year: 1976 ident: B51 article-title: The clonal evolution of tumor cell populations publication-title: Science doi: 10.1126/science.959840 – volume: 82 start-page: 2811 ident: B11 article-title: Two-photon fluorescence spectroscopy and microscopy of NAD(P)H and flavoprotein publication-title: Biophys J. ( doi: 10.1016/S0006-3495(02)75621-X – volume: 19 start-page: 111 year: 2014 ident: B46 article-title: Targeting nrf2 signaling to combat chemoresistance publication-title: J Cancer Prev. doi: 10.15430/JCP.2014.19.2.111 – volume: 88 start-page: 31 year: 2016 ident: B12 article-title: Evaluation of functioning of mitochondrial electron transport chain with NADH and FAD autofluorescence publication-title: Ukr Biochem J doi: 10.15407/ubj88.01.031 – volume: 49 start-page: 991 year: 2016 ident: B49 article-title: Association between cancer stem cell-like properties and epithelial-to-mesenchymal transition in primary and secondary cancer cells publication-title: Int J Oncol. doi: 10.3892/ijo.2016.3582 – volume: 9 start-page: 2098 year: 2017 ident: B23 article-title: A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis publication-title: Aging doi: 10.18632/aging.101304 – volume: 6 start-page: 18772 year: 2016 ident: B17 article-title: Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells publication-title: Sci Rep. doi: 10.1038/srep18772 – volume: 6 start-page: 14777 year: 2015 ident: B26 article-title: Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells publication-title: Oncotarget doi: 10.18632/oncotarget.4401 – volume: 535 start-page: 150 year: 2013 ident: B8 article-title: The human flavoproteome publication-title: Arch Biochem Biophys. doi: 10.1016/j.abb.2013.02.015 – volume: 60 start-page: 130 year: 2017 ident: B35 article-title: CDK4/6 inhibition in early and metastatic breast cancer: a review publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2017.09.003 – volume: 12 start-page: R31 year: 2010 ident: B38 article-title: Senescence evasion by MCF-7 human breast tumor-initiating cells publication-title: Breast Cancer Res. doi: 10.1186/bcr2583 – volume: 495 start-page: 1081 year: 2018 ident: B48 article-title: High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion publication-title: Biochem Biophys Res Commun. doi: 10.1016/j.bbrc.2017.11.117 – volume: 8 start-page: 68730 year: 2017 ident: B27 article-title: Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: early detection of treatment failure with companion diagnostics publication-title: Oncotarget doi: 10.18632/oncotarget.19612 – volume: 278 start-page: 2625 year: 2011 ident: B9 article-title: Flavogenomics - a genomic and structural view of flavin-dependent proteins publication-title: FEBS J. doi: 10.1111/j.1742-4658.2011.08202.x – volume: 8 start-page: 1593 year: 2016 ident: B20 article-title: Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs) publication-title: Aging doi: 10.18632/aging.100983 – volume: 12 start-page: 296 year: 2017 ident: B34 article-title: Incorporating CDK4/6 inhibitors in the treatment of advanced luminal breast cancer publication-title: Breast Care doi: 10.1159/000481656 – volume: 25 start-page: 402 year: 2018 ident: B33 article-title: Clinical development of CDK4/6 inhibitor for breast cancer publication-title: Breast Cancer doi: 10.1007/s12282-017-0827-3 – volume: 481 start-page: 306 year: 2012 ident: B52 article-title: Clonal evolution in cancer publication-title: Nature doi: 10.1038/nature10762 – volume: 370 start-page: 165 year: 2016 ident: B50 article-title: TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.10.012 – volume: 17 start-page: 862 year: 2015 ident: B15 article-title: In vivo autofluorescence imaging of tumor heterogeneity in response to treatment publication-title: Neoplasia doi: 10.1016/j.neo.2015.11.006 – volume: 128 start-page: 453 year: 2016 ident: B19 article-title: Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia publication-title: Blood doi: 10.1182/blood-2015-12-688051 – volume: 49 start-page: 611 year: 2016 ident: B45 article-title: Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis publication-title: Int J Oncol. doi: 10.3892/ijo.2016.3551 – volume: 9 start-page: 2125 year: 2018 ident: B16 article-title: Intravital imaging by simultaneous label-free autofluorescence-multiharmonic microscopy publication-title: Nat Commun. doi: 10.1038/s41467-018-04470-8 – volume: 553 start-page: 96 year: 2018 ident: B39 article-title: Senescence-associated reprogramming promotes cancer stemness publication-title: Nature doi: 10.1038/nature25167 – volume: 63 start-page: 700 year: 2017 ident: B43 article-title: Molecular portrait of metastasis-competent circulating tumor cells in colon cancer reveals the crucial role of genes regulating energy metabolism and DNA repair publication-title: Clin Chem. doi: 10.1373/clinchem.2016.263582 – volume: 4 start-page: 241 year: 2010 ident: B10 article-title: Intracellular coenzymes as natural biomarkers for metabolic activities and mitochondrial anomalies publication-title: Biomarkers Med. doi: 10.2217/Bmm.10.1 – volume: 110 start-page: 2593 ident: B44 article-title: Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis publication-title: Br J Cancer ( doi: 10.1038/bjc.2014.201 – volume: 8 start-page: 20309 year: 2017 ident: B22 article-title: Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.15852 – volume: 25 start-page: 479 year: 2018 ident: B31 article-title: Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials publication-title: Breast Cancer doi: 10.1007/s12282-018-0848-6 – volume: 5 start-page: 11029 year: 2014 ident: B5 article-title: Mitochondria as new therapeutic targets for eradicating cancer stem cells: quantitative proteomics and functional validation via MCT1/2 inhibition publication-title: Oncotarget doi: 10.18632/oncotarget.2789 – volume: 34 start-page: 9 year: 2018 ident: B30 article-title: CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.03.023 – volume: 17 start-page: 1091 year: 2018 ident: B37 article-title: Glutaredoxin-1 silencing induces cell senescence via p53/p21/p16 signaling axis publication-title: J Proteome Res. doi: 10.1021/acs.jproteome.7b00761 – volume: 48 start-page: e272 year: 2016 ident: B41 article-title: Aldehyde dehydrogenase is used by cancer cells for energy metabolism publication-title: Exp Mol Med. doi: 10.1038/emm.2016.103 – volume: 14 start-page: 113 year: 2017 ident: B3 article-title: Cancer metabolism: a therapeutic perspective (vol 14, pg 11, 2017) publication-title: Nat Rev Clin Oncol. doi: 10.1038/nrclinonc.2016.60 – volume: 177 start-page: 112 year: 2018 ident: B25 article-title: Redox responses are preserved across muscle fibres with differential susceptibility to aging publication-title: J Proteomics doi: 10.1016/j.jprot.2018.02.015 – volume: 501 start-page: 328 year: 2013 ident: B53 article-title: Tumour heterogeneity and cancer cell plasticity publication-title: Nature doi: 10.1038/nature12624 – volume: 9 start-page: 2610 year: 2017 ident: B28 article-title: Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy publication-title: Aging doi: 10.18632/aging.101351 – volume: 475 start-page: 1611 year: 2018 ident: B2 article-title: Cancer stem cells (CSCs): metabolic strategies for their identification and eradication publication-title: Biochem J. doi: 10.1042/Bcj20170164 – volume: 88 start-page: 706 year: 2013 ident: B47 article-title: Nrf2 is a potential therapeutic target in radioresistance in human cancer publication-title: Critic Rev Oncol Hematol. doi: 10.1016/j.critrevonc.2013.09.001 – volume: 10 start-page: 1169 year: 2017 ident: B36 article-title: Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer publication-title: Expert Rev Clin Pharmacol. doi: 10.1080/17512433.2017.1376653 – volume: 16 start-page: 41 year: 2017 ident: B55 article-title: Intra-tumor heterogeneity from a cancer stem cell perspective publication-title: Mol Cancer doi: 10.1186/s12943-017-0600-4 – volume: 17 start-page: 111 year: 2012 ident: B18 article-title: A detailed mammosphere assay protocol for the quantification of breast stem cell activity publication-title: J Mam Gland Biol Neoplasia doi: 10.1007/s10911-012-9255-3 – volume: 32 start-page: 216 year: 2018 ident: B29 article-title: CDK4/6 inhibitors: game changers in the management of hormone receptor-positive advanced breast cancer? publication-title: Oncology – volume: 17 start-page: 2091 year: 2018 ident: B6 article-title: A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX publication-title: Cell Cycle doi: 10.1080/15384101.2018.1515551 – volume: 11 start-page: 1161 year: 2014 ident: B14 article-title: Intracellular autofluorescence: a biomarker for epithelial cancer stem cells publication-title: Nat Methods doi: 10.1038/nmeth.3112 – volume: 1264 start-page: 263 year: 2015 ident: B13 article-title: Measurement of mitochondrial NADH and FAD autofluorescence in live cells publication-title: Methods Mol Biol. doi: 10.1007/978-1-4939-2257-4_23 – volume: 8 start-page: 67043 year: 2017 ident: B42 article-title: Aldehyde dehydrogenase 1A1 increases NADH levels and promotes tumor growth via glutathione/dihydrolipoic acid-dependent NAD(+) reduction publication-title: Oncotarget doi: 10.18632/oncotarget.17688 – volume: 7 start-page: 816 year: 2015 ident: B24 article-title: Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts publication-title: Aging doi: 10.18632/aging.100808 – volume: 18 start-page: 55 year: 2016 ident: B1 article-title: Cancer stem cell metabolism publication-title: Breast Cancer Res. doi: 10.1186/s13058-016-0712-6 – volume: 469 start-page: 314 year: 2011 ident: B54 article-title: Cells of origin in cancer publication-title: Nature doi: 10.1038/nature09781 – volume: 113 start-page: E5024 year: 2016 ident: B40 article-title: Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence publication-title: Proc Natl Acad Sci USA. doi: 10.1073/pnas.1602379113 |
| SSID | ssj0000650103 |
| Score | 2.400552 |
| Snippet | Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 677 |
| SubjectTerms | cancer stem-like cells (CSCs) Diphenyleneiodonium (DPI) glycolysis metabolism mitochondrial OXPHOS Oncology Ribociclib |
| Title | “Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30805301 https://www.proquest.com/docview/2186140570 https://pubmed.ncbi.nlm.nih.gov/PMC6370664 https://doaj.org/article/6c386c72f84941e2944e9d2e29cacc22 |
| Volume | 8 |
| WOSCitedRecordID | wos000457672100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2234-943X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000650103 issn: 2234-943X databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2234-943X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000650103 issn: 2234-943X databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELagQogL4p_wUxmJQ5EITRzHsbmVZase2GqlFmlvUWxP1JW2CcpmkXpBPfIQ8HJ9EmaSdLWLQFy4RFFiy5bn83jGHn_D2GtvlUc73oexgSiUCRShgdKEhYpLa2SsI9ex63_Kjo_1bGamG6m-KCaspwfuB25fuUQrl4lSS6wKwkgJxgt8cYVzotO-aPVsOFO9Dk4pgUHP5YNemNkv64oYC2MKnVRZtrUMdWz9fzIxf4-U3Fh6Du-xu4PNyA_6vt5nN6B6wG5PhlPxh-z71eWPMd3howuJV5c_-YhE2fCTFs75CBaLJd-DcHQyWr55zw846jV-hO5nE06gRQws5o4XledTSuBTQk8Fzk9X53XT1ebTM6hq2qt9yz82pB25veATVAWoOitPCOZd8xeP2OfD8enoKBwyLIROpqYNBViX-iQyUZmWKQiQWWbRBJEarAKhaYPIW1342HstTFx6h_5Y6rxU3qMQksdsp6oreMq49YXIHBZD-0YaC1oCyKJUwvnIKlMG7N31gOduoB-nLBiLHN0QklBOEspJQnknoYDtrSt86Zk3_l70A0lwXYwos7sPCKR8AFL-LyAF7NW1_HOcYnRuUlRQr5Y5pe2KybCNAvakx8O6qQSxl6KSDFi2hZStvmz_qeZnHY23SjK09-Sz_9H55-wODofpwsnTF2ynbVbwkt1yX9v5stllN7OZ3u1mCD4n38a_AIdtGdk |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E2%80%9CEnergetic%E2%80%9D+Cancer+Stem+Cells+%28e-CSCs%29%3A+A+New+Hyper-Metabolic+and+Proliferative+Tumor+Cell+Phenotype%2C+Driven+by+Mitochondrial+Energy&rft.jtitle=Frontiers+in+oncology&rft.au=Fiorillo%2C+Marco&rft.au=Sotgia%2C+Federica&rft.au=Lisanti%2C+Michael+P.&rft.date=2019-02-05&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=8&rft_id=info:doi/10.3389%2Ffonc.2018.00677&rft_id=info%3Apmid%2F30805301&rft.externalDocID=PMC6370664 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |